Drugmaker Tranzyme (TZYM) +11.7% premarket on news it will explore a possible sale of the...

|By:, SA News Editor

Drugmaker Tranzyme (TZYM) +11.7% premarket on news it will explore a possible sale of the company, less than two years after it went public. Two mid-stage trials of its development drug for stomach paralysis recently were dropped due to lack of efficacy.